Gilder Gagnon Howe & Co Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$54.5M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$53.8M |
| 3 |
Airbnb
ABNB
|
+$35.5M |
| 4 |
BioNTech
BNTX
|
+$22.3M |
| 5 |
NVIDIA
NVDA
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$45.6M |
| 2 |
Okta
OKTA
|
+$43.1M |
| 3 |
Roku
ROKU
|
+$38.5M |
| 4 |
Enphase Energy
ENPH
|
+$37.3M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$31.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.88% |
| 2 | Consumer Discretionary | 24.08% |
| 3 | Healthcare | 18.93% |
| 4 | Industrials | 8.2% |
| 5 | Communication Services | 7.28% |
Similar funds
Gilder Gagnon Howe & Co's Q3 2022 Portfolio in Review
As of Q3 2022, Gilder Gagnon Howe & Co held 266 positions worth $5.73B, up 2.2% from $5.61B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Gilder Gagnon Howe & Co withdrew a net $305M in Q3 2022, closing 19 positions and reducing 179 holdings. Its most notable exit was 1Life Healthcare, an estimated $23.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 32% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Gilder Gagnon Howe & Co opened a new position in Novo Nordisk worth $50M.
- Gilder Gagnon Howe & Co's largest Q3 2022 buy was Novo Nordisk: 1,004,430 shares worth $50M.
- Gilder Gagnon Howe & Co added most to Eli Lilly in Q3 2022, an estimated $54.5M increase.
- Gilder Gagnon Howe & Co's biggest Q3 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $45.6M.
- Gilder Gagnon Howe & Co fully exited 1Life Healthcare in Q3 2022, selling an estimated $23.4M.
- Gilder Gagnon Howe & Co's ten largest holdings make up 37% of its $5.73B portfolio in Q3 2022.
- Gilder Gagnon Howe & Co opened 17 new positions and closed 19 in Q3 2022.
- Gilder Gagnon Howe & Co's portfolio value rose 2.2% quarter-over-quarter to $5.73B.
Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2022, filed 14 Nov 2022.